Ainos (AIMD) Q3 2025 earnings summary

Executive summary

• Accelerated commercialization of AI-powered scent digitization (AI Nose), with pilot deployments, six industrial partnerships, and a $2.1 million subscription order for 1,400 units from ASE Technology Holding Co.

• Strategic focus on scaling AI Nose for 2026, expanding pilots, and strong visibility at major industrial exhibitions.

• Transitioned industry classification to Technology Hardware, Storage & Peripherals, reflecting a shift from biotech to digital olfaction.

• VELDONA pipeline advancing clinical trials in Taiwan for HIV-related oral warts and Sjögren's syndrome, with Orphan Drug Designation from the FDA for the HIV indication.

• Revenue growth driven by VELDONA pet supplement sales and VOC sensing products; COVID-19 test kits discontinued.

Financial highlights

• Q3 2025 revenue was $2,167, up from nil in Q3 2024; nine-month revenue reached $113,037, up from $20,729 year-over-year.

• Q3 2025 net loss was $2,931,702, a 21% improvement from $3,699,317 in Q3 2024; nine-month net loss was $10,302,714, up 1% from $10,209,149 year-over-year.

• Gross profit for Q3 2025 was $1,690, compared to a gross loss of $547 in Q3 2024; nine-month gross profit was $93,390, versus a loss of $31,945 in the prior year.

• Operating expenses for Q3 2025 were $2,785,883, down 8% year-over-year; SG&A expenses declined 22% and R&D expenses slightly decreased.

• Cash and cash equivalents as of September 30, 2025, were $1,128,217, down from $3,892,919 at year-end 2024.

Outlook and guidance

• Positioned for 2026 commercial scale-up, leveraging a growing partner ecosystem and expanding SmellTech-as-a-Service model.

• Continued investment in product development, clinical trials, and commercialization of AI Nose and VELDONA platforms.

• Management expects ongoing net losses and negative operating cash flows for at least the next twelve months; substantial doubt exists about the ability to continue as a going concern without additional funding.